"Adaptive Security - $81.0M New York-based Adaptive Security provides training and phishing simulations to help organizations strengthen human defenses against evolving cyber threats. Founded by Andrew Jones and Brian Long in 2023, Adaptive Security has now raised a total of $136.0M in total equity funding and is backed by Abstract, Andreessen Horowitz, Bain Capital Ventures, Capital One Ventures, Citi Ventures, NVentures, and OpenAI Startup Fund."
"Aeovian Pharmaceuticals - $55.0M San Francisco-based Aeovian Pharmaceuticals aims to discover, develop, and commercialize therapeutics for the treatment of rare and age-related diseases. Founded by James Peyer and Stelios Tzannis in 2012, Aeovian Pharmaceuticals has now raised a total of $142.0M in total equity funding and is backed by Apollo Health Ventures, CTI Life Sciences Fund, Foresite Capital, Hevolution, Luma Group, Sofinnova Investments, SymBiosis, The TSC Alliance Endowment Fund, venBio Partners, and Wilson Sonsini Goodrich & Rosati."
"Chai Discovery - $130.0M San Francisco-based Chai Discovery develops artificial intelligence models that predict and reprogram biochemical molecule interactions. Founded by Jack Dent, Jacques Boitreaud, Joshua Meier, and Matthew McPartlon in 2024, Chai Discovery has now raised a total of $230.0M in total equity funding and is backed by Dimension Capital, Emerson Collective, General Catalyst, Glade Brook Capital Partners, Lachy Groom, Menlo Ventures, Neo, Oak HC/FT, OpenAI, SV Angel, Thrive Capital, and Yosemite."
The week ending 12/20/25 recorded notable startup funding totaling $6.4B across 27 deals. Chai Discovery raised $130.0M to develop AI models that predict and reprogram biochemical molecule interactions and has $230.0M in total equity funding with backers including OpenAI and General Catalyst. Adaptive Security raised $81.0M for training and phishing simulations, bringing total equity to $136.0M with investors such as Andreessen Horowitz and OpenAI Startup Fund. Aeovian Pharmaceuticals raised $55.0M to advance therapeutics for rare and age-related diseases, now totaling $142.0M with life-science investors.
Read at Alleywatch
Unable to calculate read time
Collection
[
|
...
]